SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (”SaaS”) platform, reports that the platform now has more than 3 million retail investors. The SRAX-created, exclusive Sequire platform is an operating system that uses machine learning to help publicly traded companies identify and attract potential retail investors. The platform aims to be used by every publicly traded company. In addition, Sequire is building a community of retail investors who have shown interests in specific segments and industries. To view the full press release, visit https://ibn.fm/Yo6ka. Also today, the company was featured in an IBN Spotlight publication from InvestorBrandNetwork, examining how shares of SRAX (NASDAQ:SRAX) traded at a new 52-week high today of $4.43. Approximately 251,000 shares have changed hands today, as compared to an average 30-day volume of 400,000 shares.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

• SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
• SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
• SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
• SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
• SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
• SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Tuesday's trading session at $4.175, up 5.6962%, on 953,278 volume. The average volume for the last 3 months is 282,433 and the stock's 52-week low/high is $0.000000999/$0.0006.

Recent News

• InvestorNewsBreaks - SRAX (NASDAQ: SRAX) Sequire Platform Now Has 3M-Plus Retail Investors
• SRAX: The Winning Streak Continues (SRAX)
• InvestorNewsBreaks - SRAX Inc. (NASDAQ: SRAX) Featured in NetworkNewsAudio Broadcast

HempFusion Wellness Inc. (TSX: CBD.U)

The QualityStocks Daily Newsletter would like to spotlight HempFusion Wellness Inc. (TSX: CBD.U).

HempFusion Wellness (TSX: CBD.U), a leader in the health and wellness cannabidiol (“CBD”) industry, has announced an exclusive partnership with Loenbro Motorsports, one of the world’s leading race teams. The collaboration makes HempFusion CBD, a leading brand utilizing the power of whole-food hemp nutrition, and Probulin, one of the fastest growing probiotic brands in the U.S. according to SPINs reported data, the exclusive sponsors in their respective categories for the 2021 racing season. To view the full press release, visit http://cnw.fm/vPUOO

HempFusion Wellness Inc. (TSX: CBD.U) is a leader in the health and wellness CBD industry, providing innovative and diversified proprietary formulations utilizing the power of whole-food hemp nutrition.

Invested heavily in regulatory compliance, HempFusion aims to consistently meet and even exceed the high standards required by retailers and consumers – putting safety, quality and consistency first. In support of these efforts, the company is U.S. Hemp Authority Certified and is a current board member of the U.S. Hemp Roundtable, a coalition of leading companies committed to advancing safe hemp and CBD products.

HempFusion reported 1,750 shareholders and $18.3 million in cash as of June 30, 2020 – the second-largest cash position in its sector – with no debt. Looking ahead, the company is currently preparing to launch an IPO directly onto the Toronto Stock Exchange (“TSX”) senior board, where it has already reserved ticker symbol ‘CBD.U’. Learn More About HempFusion Upcoming IPO.

HempFusion is headquartered in Denver, Colorado.

HempFusion’s Proprietary Wellness Portfolio

The diverse product portfolio showcased by HempFusion includes 46 products that are currently on shelves. The company’s leading offerings include HempFusion-owned Biome Labs, HF Labs and Probulin. Due to the time and resources allocated to increasing the compliance of these proprietary products, HempFusion may have a competitive advantage and create additional retail opportunities that are not available for other CBD companies.

HempFusion’s Diversified Revenue Pipeline

HempFusion’s focus and investment into regulatory compliance has opened doors to major food and drug mass or big box retailers that are not available to other CBD companies. This strategic approach includes five distinct channels:

• Natural Health Retailers
• eCommerce
• Big Box / Food and Drug Mass
• Doctor Practitioner
• Convenience

HempFusion’s Line of Products

HempFusion’s branded line of products is based on the company’s proprietary Whole Food Panoramic Full-Spectrum Hemp Complex. Each product is condition-specific, targeting needs such as sleep, energy and stress.

All of HempFusion’s products are made from DNA-verified, European Union registered, non-GMO, organic industrial hemp. The company’s offerings span multiple product categories, including:

• Tinctures and capsules – These offerings make up the most popular product category in the $4 billion U.S. CBD market.
• OTC topicals – HempFusion is one of the few CBD companies marketing FDA Drug Listed Topicals. The FDA compliance standards ensure that these products meet the standards set by larger national retailers.
• Condition-specific OTC products – HempFusion has OTC products that are condition-specifically targeted, including:
  • OTC Pain Products – The global pain relief market for topicals is projected to reach $13.3 billion by 2025, with a CAGR from 2018 to 2025 of 7.4%.
  • OTC Eczema Products – The global dermatitis market is projected to reach $13.6 billion by 2026.
  • OTC Acne and Aging/Beauty Products – The global market for beauty and anti-aging products is currently estimated at $1.08 trillion.
  • OTC First Aid and Wound Healing Products – In 2019, the 10 top-selling first aid ointments in the United States generated over $650 million in sales.

Probulin Probiotics and Digestive Enzymes

Probulin Probiotics is a 100% wholly owned subsidiary of HempFusion Wellness Inc. and is currently one of the fastest growing probiotics brands in the United States, according to Spins syndicated data.

The Probulin product line addresses a wide range of consumer needs, including daily care, total care, women’s health and children’s products. The probiotics market represents a growing opportunity, as it is estimated to reach $7 billion globally by 2022.

Because of the diverse offerings of the Probulin line, it serves as HempFusion’s gateway to retailers who may not currently carry CBD products.

This ‘Trojan Horse Strategy’ is intended to allow the company to establish, develop and build relationships among these retailers. By achieving approved vendor status, the company may be able to facilitate faster onboarding times, enabling accelerated access to its CBD products in the future.

HF Labs and Biome Research – Doctor and Practitioner Product Lines

The HF Labs and Biome Research product lines are directed toward doctors and practitioners and cater to hospitals, compounding pharmacies and free-standing dispensaries. With an estimated target market of 28,000+ integrative medical doctors and 70,000+ licensed chiropractors in the United States, these offerings create a unique market opportunity as HempFusion continues to broaden its footprint in the CBD industry.

Research on CBD and Human Safety

HempFusion is one of 12 CBD companies selected to participate in ValidCare’s groundbreaking study regarding CBD and human safety, which is expected to be complete by the end of October 2020. The study is designed to address previous questions from the FDA regarding CBD products.

As part of this study, HempFusion and the other selected companies will be conducting human trials to determine if the daily use of full-spectrum hemp-derived CBD or CBD isolate impacts the human liver.

Management Team

Jason Mitchell, N.D., is the co-founder, Director and CEO of HempFusion. He has over 20 years of experience in the natural products industry and is a naturopathic doctor certified by the ANMCB. Mitchell received his doctorate from the Trinity College of Natural Health and is a member of the American Naturopathic Medical Association and the CNHP. He is an expert in supplemental formations and was responsible for successfully creating and launching over 300 industry-leading products during his 15-year tenure at Country Life Vitamins.

Ian DeQueiroz is the Chief of Brand Strategy & Partnerships and a Director for HempFusion. He is a serial entrepreneur with experience in early-stage cannabis and hemp companies. In 2010, he acquired his first cannabis CO2 extraction company in the United States. DeQueiroz has facilitated the licensing process for many companies in the United States, as well as one of Jamaica’s premier cannabis companies, Epican Medicinals Ltd.

Jon Visser is HempFusion’s Chief Revenue Officer. He has over 25 years of experience in all areas of sales and marketing, with a proven track record of consistently driving growth across all major channels. Visser was previously the Senior Vice President of Sales at Navajo Inc., a multi-national manufacturer/distributor of brands like Pennzoil Automotive Supplies, Piranha Eyewear and Navajo Inc., the largest distributor of trial- and travel-sized health and beauty products in the United States. Visser grew annual sales from $60 million to $128 million in less than three years while at Navajo Inc.

Bruce Valentine Jr. is the Chief Financial Officer of HempFusion. He has a proven track record working with high-growth companies and was named CFO of the Year in 2013 by the Northern Colorado Business Report. Valentine is the former CFO of Otter Products and has over 15 years of financial management experience.

Ola Lessard is the Chief Marketing Officer of HempFusion and is also the President of the U.S. Hemp Roundtable. She has experience in marketing creative and effective brand strategies. She is a former Vice President of Marketing at Barlean’s, an award-winning supplements provider based in Washington.

Nancy Angelini is the Director of the Doctor/Practitioner Channel. She has over 25 years as an active, licensed practitioner. Angelini travels the country as a lecturer and product manager. She is responsible for opening doors to some of the largest doctor/practitioner networks in the United States.

Daniel Brody is the Chief Corporate Officer of HempFusion. He is the co-founder and former Vice President of The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF). Brody has been instrumental in listing multiple world-class cannabis companies, including TGOD, Emblem Corp. and Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF). Before joining the cannabis industry, he spent seven years working at two leading Canadian brokerage firms.

HempFusion Wellness Inc. (TSX: CBD.U), closed Tuesday's trading session at $1.83, up 5.78%, on 163,734 volume. The average volume for the last 3 months is 360,841 and the stock's 52-week low/high is $1.35/$2.15.

Recent News

• CBDNewsBreaks - HempFusion Wellness Inc. (TSX: CBD.U) Enters Exclusive Partnership with Leading Race Team Loenbro Motorsports
• QualityStocksNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) Secures Inclusion in Two Cannabis ETFs
• QualityStocksNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) Enters Doctor Practitioner Space with Large-Scale Distribution Agreement

Brain Scientific Inc. (OTCQB: BRSF)

The QualityStocks Daily Newsletter would like to spotlight Brain Scientific Inc. (OTCQB: BRSF).

Brain Scientific (OTCQB: BRSF) vice president of marketing Stuart Bernstein has authored a DotMed Healthcare Business News article titled “COVID’s influence on neurology drives need for disposable technologies.” In the article, Bernstein notes both time management and infection control as key factors in the growing need for disposable technologies. To view the full article, visit http://ibn.fm/o67K4. Also today, the company was featured in a publication from BioMedWire, examining how the COVID-19 pandemic has accelerated several changes to American culture, many of which appear to be here to stay. According to Harvard experts, some of those changes include movement towards a cashless society, increased remote work, the decline of brick-and-mortar retail, and a new approach to health that includes an acceptance of telemedicine and artificial intelligence (“AI”) (https://ibn.fm/f9IJ5). Brain Scientific (OTCQB: BRSF) is positioned to benefit from that growing acceptance of AI as it focuses on modernizing brain diagnostics.

Brain Scientific Inc. (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

The company’s proprietary, clinical-grade neurological devices are supported by its intellectual property portfolio featuring patents in the United States, China and Europe.

Brain Scientific’s first commercialized devices, NeuroCap(TM) and NeuroEEG(TM), are designed to disrupt the current electroencephalogram (EEG) market by offering cost-effective and disposable substitutes to existing solutions, allowing medical professionals to collect diagnostic information quickly.

The company’s goal is to improve diagnostics by leveraging artificial intelligence and machine learning processes to analyze a database of brain readings as a method of detecting seizures and dementia. The company is also working to improve patients’ access to neurological care.

Headquartered in New York, Brain Scientific and its predecessor (and now wholly owned subsidiary, MemoryMD Inc.) was founded in 2015 and went public in 2018.

Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

NeuroCap(TM) – Disposable EEG Headset

The NeuroCap is a disposable pre-gelled EEG headset featuring 22 electrodes and 19 active EEG channels, all adhering to the international 10-20 system. The NeuroCap was FDA-cleared in 2018. The headset can be used for recording EEGs in virtually any setting, including urban and rural emergency departments, neurology clinics, urgent care clinics, ICUs, nursing homes, assisted living facilities and remote clinical research labs.

Through a universal cable adapter, the NeuroCap is compatible with other EEG amplifiers. The cap also works in parallel with Brain Scientific’s NeuroEEG amplifier, initiating EEG studies in less than five minutes.

The company is currently seeking FDA approval for additional features for the NeuroCap, as the device has the potential to fill a gap in EEG testing availabilities during the current coronavirus pandemic: in October 2020, Brain Scientific filed an Emergency Use Authorization (EUA) application. The EUA is required for the rapid distribution of the NeuroCap device to emergency departments, intensive care units and other treatment centers to administer prescriptive EEGs safely on critically ill patients or those suspected of being diagnosed with COVID-19.

With more than 80 percent of hospitalized patients infected with COVID-19 displaying neurological symptoms, the NeuroCap could prove to be a valuable device by offering fast testing with limited contact between technicians and patients.

NeuroEEG(TM) – Miniature and Portable Wireless EEG Amplifier

The NeuroEEG is a compact, portable and affordable wireless EEG amplifier intended for prescription use. The 16-channel, FDA-cleared, clinical-grade device acquires, records, transmits and displays electrical brain activity for patients of all ages.

Both the NeuroCap and NeuroEEG are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific.

Products in Active Development

Currently, Brain Scientific and MemoryMD are working on leveraging their existing products and drawing from ongoing research to develop and commercialize the next generation of solutions for the brain diagnostics market. The devices under development are being designed to address the following issues:

Routine EEG

• NeuroCap-8 is an 8-channel EEG cap. The reduced number of electrodes is vital in emergency room situations, where the time it takes to set up the EEG is critical.

Pediatric EEG

• NeuroCap Pediatric is positioned to become the first disposable and pre-gelled headset available for the pediatric market.

Long-Term Monitoring

• NeuroCap LTM for adult and pediatric patients is a disposable cap designed to monitor rhythmic and periodic patterns for up to 72 hours, providing essential diagnostic capabilities.
• NeuroEEG 24 Channel Amplifier is a portable and wireless amplifier with over 24 hours of battery life.

Artificial Intelligence

• Brain E-Tattoo is a minimally invasive four-channel EEG electrode designed for long-term monitoring.
• An AI database of brain biomarkers collects data on both normal and abnormal brain data to detect neurological diseases. The goal is for machine learning algorithms to enhance understanding of brain-behavior related to epilepsy, memory dementia and pre-Alzheimer’s diagnostics.

Telemedicine

Brain Scientific is expanding the vision for telemedicine in neurology. The company aims to address the current acute neurologist shortfall (20 states have less than 10 neurologists per 10,000 patients) through the use of teleneurology.

 

Partnership with Marketing Brainology

Brain Scientific has a longstanding partnership with Marketing Brainology, a neuromarketing firm using neuroscience approaches to understand consumer behavior. In 2019, Marketing Brainology conducted a study using NeuroCap and NeuroEEG to determine the most effective Super Bowl commercials.

“Thanks to Brain Scientific’s NeuroCap and NeuroEEG, we are able to better understand the art and science of the human decision-making process,” Michelle Adams, Ph.D, Founder of Marketing Brainology, stated in a news release.

In April 2020, Marketing Brainology again conducted a study leveraging Brain Scientific’s disposable EEG cap to determine how brains were reacting to COVID-19 messaging. Subjects were presented with multiple media impressions, and Marketing Brainology analyzed their responsive biomarkers. The results identified the most effective messaging for engaging with an audience during a crisis.

Market Outlook

The current global market for EEG devices is estimated at $956.1 million. It is expected to rise with a CAGR of 8.7% from 2019 to 2026, reaching $1.6 billion in value by 2026, according to Grandview Research.

In total, there are approximately 6,150 hospitals in the U.S., according to the American Hospital Association. Critically, though, just 254 of those hospitals are certified Level 4 Epilepsy centers with 24/7 EEG coverage. Since very few non-Level 4 centers have extensive EEG tech coverage, this creates a significant opportunity for Brain Scientific to bridge the gap by providing over 5,900 hospitals with lower cost amplifiers and disposable EEG caps.

The company also see opportunities to work with other businesses, such as EEG manufacturers hoping to package Brain Scientific’s solutions with their products, which could greatly expand Brain Scientific’s addressable target market.

Management Team

Dr. Baruch “Boris” Goldstein, Ph.D., is co-founder and Chairman of Brain Scientific. He is a seasoned executive with a proven talent for aligning global business strategies with established and emerging management teams. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital for the development of innovative companies and startups in diverse industries, including financial services, biomedicine, alternate energy and new materials, as well as groundbreaking work in artificial intelligence. His recent achievements include important advancements in neurology and unlocking the potential of AI correlations and machine learning applied to life sciences and medical research. He built a suite of first-to-market companies as a technology-oriented leader, including Ryah Medtech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. He also co-founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov, Ph.D., is a Director of Brain Scientific and a partner at HRA Capital. Before joining HRA Capital, Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research. His scientific background includes a bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. He earned his Ph.D. in neuroscience from Columbia University – College of Physicians and Surgeons in New York.

Stuart Bernstein is the company’s Vice President of Marketing. He was recently named to the role after spending the first part of his professional career in senior technical management roles with Fortune 500 companies such as NCR (NYSE: NCR), IBM (NYSE: IBM) and Control Data Corp. He was the CEO of BioSignal, an EEG medical device company. He is also a co-founder of several software engineering and telemedicine firms. One of them, Brain Saving Technology, is now Specialist on Call (SOC Telemed) – a leading telemedicine company that powers over 850 facilities for teleneurology, telepsychiatry and critical care telemedicine with over 200 physicians.

Brain Scientific Inc. (OTCQB: BRSF), closed Tuesday's trading session at $1.50, up 3.4483%, on 1,200 volume. The average volume for the last 3 months is 14,017 and the stock's 52-week low/high is $0.010499999/$0.1849.

Recent News

• BioMedNewsBreaks - Brain Scientific Inc. (BRSF) Marketing VP Authors Article on Increasing Need for Disposable Technologies
• Brain Scientific Inc. (BRSF) E-Tattoo Will Offer AI Solutions for Neurology
• BioMedNewsBreaks - Brain Scientific Inc. (BRSF) Featured in Med-Tech Innovation Article

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0)

The QualityStocks Daily Newsletter would like to spotlight MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0).

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, is involved in several upcoming investment and industry conferences, and has released information regarding three upcoming investment and industry conferences in which it will be participating. To register and the full CSE Tech Tuesday event, visit https://ibn.fm/xK99c. To view the World Agri-Tech Summit, visit https://ibn.fm/hp6mN. To view the Banff Capital Conference, visit https://ibn.fm/Gt4Ey. To view the full press release, visit https://ibn.fm/I5rOZ.

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is an agricultural biotech company focused on developing and commercializing natural biological solutions for high-value crops, including fruits and vegetables. The company uses novel compounds from the mustard plant to provide superior and safer alternatives to current synthetic chemicals used as pesticides, fungicides and nematicides. Management & advisors own 22% of the company’s 37 million shares outstanding.

Leveraging its innovative platform, MustGrow effectively extracts the natural defense mechanisms of the mustard seed for broad use in crop production and protection. The company uses components of mustard seed to provide high quality, organic pest control to growers facing challenges associated with soil-borne diseases and pests like nematodes. This company’s all-natural, effective, safe and easy-to-use solution is ideal for farmers looking to raise healthy crops without chemical pesticides amid growing concerns worldwide over the negative effects of chemical pesticide solutions.

MustGrow, which went public in 2019, was founded in Saskatoon, Canada, and is currently focused on disrupting the $65 billion global pesticide market with its 100% owned and patented mustard-derived technology. Canada produces 28% of the global mustard crop and is the world’s largest exporter, with a 57% market share.

TerraMG and Pipeline

The company’s technology extracts the mustard plant’s natural organic compounds, which, when combined with water, form Allyl isothiocyanate (AITC) and serve as a natural defense mechanism for the plant against pests and diseases. MustGrow’s mustard-derived technology acts as both a natural bio-pesticide and as a non-selective bio-herbicide.

There are currently more than 110 independent third-party trials that confirm the safety and efficacy of MustGrow’s solutions, potentially positioning the company as a leading provider of safe plant protection solutions in a market that is gradually eliminating the use of chemical compounds.

MustGrow’s primary product at the moment is the new liquid formulation TerraMG, which has the potential to compete against existing chemistries on both efficacy and price. Its initial target market is as a pre-plant soil bio-pesticide for use with higher-value crops such as fruits and vegetables. This liquid formulation is safe and easy to transport and has already demonstrated its efficacy against several pests and diseases.

In addition to its use as a pre-plant soil treatment, TerraMG has significant potential for multiple applications in several other markets, which is expected to aggressively expand the company’s IP portfolio. MustGrow has already confirmed or is in the process of testing multiple applications of TerraMG, including fruit and vegetable soil fumigation ($1.2 billion estimated global market), container fumigation ($2 billion estimated global market), tobacco nematode and disease fumigation ($4 billion estimated global loss), non-selective herbicide ($13 billion estimated global market), food-borne pathogens ($15 billion estimated global market) and more.

The company anticipates registration approval for the liquid formulation (TerraMG) as a pre-plant bio-pesticide for soil-borne diseases and pests from the EPA (United States) and PMRA (Canada) in 2021. The company already has EPA and PMRA approval for the product’s granular form.

Currently, MustGrow’s pipeline also includes:

• TerraMG, a pre-plant soil bio-pesticide, for:
  • Fruit & Vegetable – currently in Phase 4
  • Turf & Ornamental – currently in Phase 4
  • Tobacco – currently in Phase 4
  • Potatoes – currently in Phase 4
  • Canola – targeting Clubroot Disease – currently in Phase 3: Advanced Development/Field Trials
  • Bananas – targeting Fusarium wilt TR4 – currently in Phase 1: Proof of Concept/Laboratory
  • Pulse Crops – targeting Aphanomyces – currently in Phase 1: Proof of Concept/Laboratory
• Non-Selective Bio-Herbicide – targeting noxious or resistant weeds – currently in Phase 2: Early Development/Greenhouse
• Storage Bio-Pesticide for Bulk Grain, Fresh Produce – targeting toxins, diseases and insects – currently in Phase 1: Proof of Concept/Laboratory
• Storage Bio-Pesticide for Shipping Containers – targeting fungus, invasive pests and diseases – currently in Phase 1: Proof of Concept/Laboratory
• Bio-Pesticide for Foodborne Pathogens – targeting E. coli, salmonella, Listeria, human pathogens, etc. – currently in Phase 1: Proof of Concept/Laboratory

Market Opportunity

The protection of crops with synthetic chemical pesticides represents a $65 billion-dollar global market that is expected to grow in the coming years as the global population grows and needs more food. This number doesn’t include bio-pesticide sales, which are projected to increase to $8.5 billion by 2025, with a CAGR of 14.7%. MustGrow, with its natural bio-pesticide, is targeting not only the bio-pesticide market, but also the global synthetic chemical market so as to help replace harmful synthetic pesticides and provide a natural biologic that has the efficacy of controlling pests and disease compared to synthetic chemicals in some instances.

Management Team

Corey Giasson is the President, CEO and Director of MustGrow. He is an entrepreneur focused on the agriculture, mining, real estate and oil/gas industries, primarily in the Canadian province of Saskatchewan. Giasson is co-founder and director of Legacy Capital Corp. This private equity company focuses on participating in management buyouts of strong, sustainable cash flowing businesses. He has an MBA and B.Sc. in Agriculture Economics from the University of Saskatchewan.

Colin Bletsky is COO and Director of MustGrow. He grew up in Eastern Saskatchewan on his family’s third-generation farm, growing canola, wheat and oats. The majority of his time is spent helping other organizations and farmers grow their businesses – locally and globally. Bletsky has a Bachelor of Science in Agriculture from the University of Saskatchewan and executive education from the London School of Business and INSEAD.

Todd Lahti is the company’s CFO. He has extensive experience evaluating and managing biotech, agricultural and oil/gas start-up companies by working directly on financing transactions, mergers and acquisitions, business development, corporate strategy, technology transfer and operations setup. Lahti is a Chartered Financial Analyst and a Chartered Professional Accountant.

Brad Munro is Chairman of MustGrow. He is the President and CEO of Bittercreek Capital Corp., a private investment and advisory firm. He has extensive corporate finance and investment experience in the natural gas and oil industries, among others. Munro has a Bachelor of Commerce from the University of Saskatchewan.

MustGrow Biologics Corp. (OTCQB: MGROF), closed Tuesday's trading session at $1.25, up 4.1667%, on 35,246 volume. The average volume for the last 3 months is 73,745 and the stock's 52-week low/high is $0.000099999/$0.01195.

Recent News

• BioMedNewsBreaks - MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Trio of Upcoming Investment, Industry Events
• Half of All Covid-19 Medical Workers at Risk of Mental Health Issues, New Research Shows
• BioMedNewsBreaks - MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Promising Results from CyberAgrot Study

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has been rated as a “Buy” in the first analyst coverage report released by equity research firm Litchfield Hills Research LLC. POAI was listed as a “Buy” under the report’s three-tiered (buy, hold, sell) rating system. Litchfield Hills Research strictly follows FINRA standards for quality and objectivity, and the research firm has certified that the publication is compliant with FINRA research rules 2241, 3110. To view the full report on POAI, visit https://ibn.fm/NE2yB. To view the full press release, visit https://ibn.fm/IZc2Y.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

• A database of clinically validated historical and outcome data from patient tumors
• An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
• A “smart” patient-derived tumor profiling platform
• An in-house bioinformatics artificial intelligence (AI) platform
• A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
• An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Tuesday's trading session at $1.23, up 4.2373%, on 5,415,522 volume. The average volume for the last 3 months is 2,235,922 and the stock's 52-week low/high is $0.031099999/$0.189999997.

Recent News

• BioMedNewsBreaks - Predictive Oncology (NASDAQ: POAI) Ranked as Buy in Litchfield Hills Recent Analyst Report
• Predictive Oncology (NASDAQ: POAI) Subsidiary Working to Individualize, Improve Ovarian Cancer Treatment Options
• BioMedNewsBreaks - Predictive Oncology Inc. (NASDAQ: POAI) Enters Strategic Contract with Large Pharmaceutical Company

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)

The QualityStocks Daily Newsletter would like to spotlight Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF).

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) was featured today in a publication from BioMedWire, examining how, after a few failed attempts at getting patients who would agree to see a telehealth psychiatrist, Jennifer Severe, a psychiatrist who had helped introduce telehealth initiatives at the University of Michigan outpatient clinic, and her colleagues were flooded with numerous videos chats after the pandemic hit. Non-urgent healthcare in Michigan was forced to go digital, with phone calls and video chats becoming the primary means for patients to communicate with their psychologists and psychiatrists. Nine months later, this is how a majority of patients have operated.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures. Its initial focus is on bladder cancer.

The company’s first product is the i/Blue Imaging™ System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons’ ability to visualize and remove cancer cells.

Founded in 2016 and headquartered in Boston, Massachusetts, the company works to enhance its market potential by expanding its technology to multiple endoscopic indications, such as laparoscopic, colorectal and thoracic procedures, accommodating multiple contrast agents and illumination sources.

i/Blue Imaging™ System

The conventional method used for visualizing bladder cancer during surgery is an endoscopic procedure called a cystoscopy. This procedure uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Blue light cystoscopy uses blue-filtered white light, which addresses the limitations of white light (such as detecting flat tumors and the fine edges that may result in cancerous cells being left behind during removal).

Blue light uses a contrast agent that causes cancer cells to fluoresce when illuminated. Surgeons are then able to more effectively visualize and resect the margins of bladder tumors to reduce the risk of recurrence. Notably, the use of the white light is still necessary during a blue-light procedure so that the surgeon can orient their position within the bladder.

Imagin Medical’s i/Blue Imaging System addresses the limitations of both white and blue light cystoscopies. The i/Blue System combines the white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in real-time, without the necessity to switch back and forth between the two images.

The i/Blue Imaging System is unlike other methods available on the market today. It is external to the body and can attach to almost any endoscope model currently in use. This way, hospitals adopting Imagin Medical’s technology have the ability to use their current endoscopes without the need to purchase new equipment.

Bladder Cancer Prevalence

The company’s initial focus is bladder cancer, which is the sixth most prevalent form of cancer in the United States. In 2020, the number of new bladder cancer cases is expected to total 81,400, accounting for 4.5 percent of all new cancers diagnosed. The death rate in 2020 for cancer deaths associated with the bladder is forecast at 17,980, or 3% of all cancer-related deaths (https://ibn.fm/qLi3l).

Bladder cancer also has one of the highest recurrence rates among all forms of cancer, leaving about 600,000 people in fear that their cancer will return, according to Imagin Medical. The company is committed to addressing this issue, and i/Blue demonstrations have indicated that the use of both white and blue light can enhance accuracy of detection and removal of cancer cells, potentially lowering recurrence rates.

Based on Verified Market Research, the global bladder cancer research market was valued at $3.43 billion in 2018. It is estimated to grow with a CAGR of 4.03% through 2026, resulting in a projected $4.71 billion market (https://ibn.fm/rI7G6).

Management Team

E. James Hutchens is the Chief Executive Officer of Imagin Medical Inc. He is a proven entrepreneur with over 30 years of experience in management in the medical technology industry. Hutchens served as a managing partner with Origin Partners, a $55 million early-stage venture capital fund. He was also the founder and CEO of both Microsurge Inc. (a venture-backed minimally invasive surgical company) and Choice Therapeutics (an advanced wound-care company). He is a former member of the Board of Directors of the Brigham and Women’s and Faulkner hospitals. Hutchins holds a BS in Business Administration from Boston University.

John Vacha is the company’s Chief Financial Officer. He has 20 years of experience in the health care industry. Prior to Medtronic’s acquisition of Intact Medical Corp. in 2017, Vacha was the company’s President, CEO and a board member for seven years. He is a licensed CPA in Massachusetts. Vacha has an MBA and an MS in Accounting from Northeastern University in Boston. He is also a serving member of the Board of Directors at the South Boston Health Center. He currently has two patents in electrosurgical instrumentation.

Michael G. Vergano is the Director of Operations of Imagin Medical. He has been the President of The Harvest Group Inc. since 1998, where he has provided consultant services for startups and major corporations. Vergano has over 30 years of experience in the medical device industry. He has held management positions at Microsurge Inc., Ciba Corning Diagnostics and Boston Scientific Corp. He is currently the holder of 11 medical device patents and holds a BS in Mechanical Engineering from Tufts University.

Pam Papineau is the company’s Director of Regulatory Affairs. She has over 30 years of experience in quality and regulatory affairs with Boston Scientific, Baxter and Cogentix. She has served as a consultant on various devices including imaging, endoscopy, orthopedic, GI/GU and cardiovascular applications. Papineau has successfully prepared dozens of FDA pre-market and EU submissions to support CE marking of a broad spectrum of medical devices. She is an ASQ Certified Quality Engineer, a Certified Biomedical Auditor, a Certified Quality Auditor and an ISO 13485:2016 Lead Auditor, and she is certified by the Regulatory Affairs Professional Society – U.S., EU and Canada. Papineau works with the company’s legal counsel to prepare pre-submission meetings with the FDA and activities through the regulatory approval process.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), closed Tuesday's trading session at $0.7061, up 8.6308%, on 29,954 volume. The average volume for the last 3 months is 45,384 and the stock's 52-week low/high is $0.219999998/$1.10000002.

Recent News

• Study Shows Patients Want Mental Health Care to Remain Online Post-Coronavirus
• Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Contracts Torrey Hills Capital to Boost Awareness of Its Proprietary Cancer Visualization Technology
• Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Enters 2021 with Optimism for Its Cancer Imaging Technology

InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: ISGIF)

The QualityStocks Daily Newsletter would like to spotlight InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: ISGIF).

InsuraGuest Technologies (TSXV: ISGI) (OTCQB: ISGIF) today announced that it has been approved by FINRA for quotation in the United States. The company's common shares began quotation on the OTCQB today, Feb. 2, 2021, at the opening of the market under the stock symbol "ISGIF" and will remain listed on the TSX Venture Exchange under the ticker symbol "ISGI." To view the full press release, visit https://ibn.fm/PN36M

InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: ISGIF) is a leading global SaaS (Software-as-a-Service) company leveraging its proprietary, flagship insurtech (insurance + technology) software, InsuraGuest, which is integrated with the property management systems of hotels and vacation rentals to deliver custom Hospitality Liability coverages.

InsuraGuest’s Hospitality Liability coverages are purchased by hotels and vacation rental properties, which can address claims from guests and their room occupants. The combination of the integrated software and customized insurance provides the property liability coverages the guests benefit from in the event a loss is incurred during their stay.

The Hospitality Liability policy is offered through integration of InsuraGuest’s API with the clients’ property management systems. InsuraGuest’s platform is currently capable of integrating with approximately 71 different hotel and vacation rental property management systems, giving it access to millions of rooms worldwide.

InsuraGuest continues to pursue expansion opportunities in the United States, and has plans to expand to its distribution platform and Hospitality Liability coverages to the United Kingdom and Europe regions by third quarter 2020, as well as expansion into Asia by the end of 2020.

Protection that Enhances the Guest’s Experience

InsuraGuest’s Hospitality Liability coverages add a layer of protection for the property on a primary basis, should a guest experience an accident or theft while staying at an InsuraGuest member hotel or vacation rental property.

Market Opportunity

The U.S. hotel industry generated more than $218 billion in annual revenues in 2018, an increase of $10 billion from the previous year, according to STR’s 2019 HOST Almanac. The European market is more than double the size of the U.S. market. According to Oxford Economics, there were 6.4 billion nights stayed in the world, with 2.6 billion hotel nights stayed in Asia, 2.8 billion nights stayed in Europe, and 1.1 billion stayed nights in the United States. Additionally, $100 billion was spent on vacation rentals in the United States, where there approximately 4.5 million second homes are being managed by a third-party rental company.

With distribution in Europe and the United States, InsuraGuest’s combined demographics will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.

Within this burgeoning, high-demand industry is risk of liability to guest injury. For example, gym injuries are among the top five most common hotel accidents. Without proper hedges in place, the property may be liable in a personal injury claim or lawsuit that are not the properties fault.

Though the potential for accidents, slip and falls and mishaps can be widespread, it can be covered under the InsuraGuest Hospitality Liability policy to provide guests a worry-free and enjoyable stay that potentially increases loyalty for the property.

Investment Consideration

• Targeting hotels and vacation rentals, a multi-billion-dollar industry
• Providing the first line of defense in case of accident, loss or death
• Expanding distribution reach with footing in European hotel and vacation rental markets
• Expansion into Asia by 2020

Executive Team

Douglas Anderson, Chairman & Chief Executive Officer
Douglas Anderson has been a businessman in the real estate industry for nearly 30 years. His business expertise includes master planning and development implementation for larger-scale resorts, business parks and commercial developments across the USA and two provinces in Canada. His business endeavors include the founding of the 7th larger private equity fund in America focusing on multifamily and senior care (ROC Fund/Bridge IPG Fund). He serves as chairman/founder of a golf and winter sports ski holding company with operations in four major east coast markets and British Columbia, Canada.

Anderson earned a Bachelor of Science in consumer studies with an emphasis in architecture as an undergraduate at the University of Utah. He subsequently earned his MBA. He also attended a three-year OPM Program a postgraduate business education at Harvard Business School in Boston. Anderson is an avid skier and outdoor enthusiast.

Logan Anderson, CFO & Director
Logan Anderson (bachelor’s degree in communications, accounting and economics) holds the designation of ACA with the Chartered Accountants of Australia and New Zealand. He began his career as an associate chartered accountant in New Zealand and then Canada. This was followed by his position as controller of a management services company which was responsible for the management of numerous private and publicly traded companies. Since 1993, Anderson has served as president of Amteck Financial Corp. (and its predecessors), a private financial consulting services company servicing both private and public companies. He is a former director of 3D Systems, Inc. (NYSE: DDD), and was formerly a founder, officer, and director of Worldbid.com. Anderson has also been involved in raising funds for numerous private and public companies in all stages of their development and has been an officer and director for numerous public and private companies over the past 40 years.

Charles James Cayias, President & Director
Charles James Cayias is also the president and owner of Charles James Cayias Insurance Inc. He is a third-generation insurance professional whose creativity and artistic vision have enabled him to establish a full-service agency combined with the personal service each client deserves. His outstanding people skills, honesty, integrity and fairness are evident by his loyal and growing clientele, the majority of which are referrals who become long-time customers and friends. Cayias began his insurance career in the early 1970s and has been licensed since 1977. He is licensed in all 50 states and specializes in niche programs. He has extensive expertise in all aspects of the insurance industry including commercial insurance, employee benefits, workers’ compensation, professional liability, risk management and bonding.

Tony Sansone, COO & VP of Finance
Tony Sansone has over 30 years of financial, operations and business development experience which includes serving as CFO in the health care, foodservice distribution, manufacturing and technology sectors, including public company experience. He has held senior finance positions in the banking, telecommunications, medical products, and food & drug retailer industries, closing over $430 million of private debt, equity and line of credit financings and over $350 million of a merger, acquisitions, real estate and state incentive transactions, including due diligence, negotiations, closing, and integration. Sansone coordinated and was the executive sponsor for four ERP implementations and multiple other best-in-class software & technology solutions. He received his MBA from the University of Utah and a Bachelor of Science in accounting from Utah State University. Sansone also currently serves as president-elect of the Utah Chapter of Financial Executives International and a past president and current member of the board of trustees for Catholic Community Services of Utah. He is the proud father of three children.

Christopher J. Panos, Vice President & Director
Christopher J. Panos is a highly competitive sales professional with over 15 years of territory manager sales experience and an award-winning record of achievements. He is exceptionally well organized with a proven work history that demonstrates self-discipline, superb communication skills, and the initiative to achieve both personal and corporate goals. Panos is successful in building relationships with a large network of industry professionals in order to grow and maintain new and existing business, exceed new sales objectives and provide in-depth product training to authorized dealers and sales personnel.

Alexander Walker III ESQ, Corporate Counsel & Director
Alexander Walker III ESQ has served as director of the company since September of 2018 and as counsel to the company since July of 2018. Walker is an attorney and has been a member of the Utah Bar Association since 1987 and a member of the Nevada State Bar since 2003. His practice has involved general business litigation, in both federal and state courts, and transactional work, including securities offerings and registration, corporate formation and periodic reporting compliance. Walker has provided legal services to emerging businesses throughout his carrier and at times has served as an officer and board member as well as legal counsel public companies. His duties as legal counsel for a public company engaged in the business of ownership and operation of coal-producing properties in the western United States included oversight of corporate-related legal matters including securities reporting, corporate compliance, federal and state mining regulation, and employment law oversight. He also has served as the chair of the Mining Committee of the Energy, Natural Resources and Environmental Law Section of the Utah State Bar, a member of the board of directors of the South East Utah Energy Producers Association, the co-chair of the board of the Western Energy Training Center, a board member of the Utah Supreme Court Committee to Review the ABA Recommendations Regarding the Office of Professional Conduct, and a board member of the University of Utah Crimson Club.

Jennifer Epperson, Vice President of Sales
Jennifer Epperson has over 20 years of B2B sales experience with exceptional success history. She has grown and developed sales territories across multiple industries. Her ability to find and develop strategic relationships has given her top-level performance throughout her career. Epperson’s passion and knowledge provide an inherent ability to connect and retain relationships for the growth of the company. Throughout her professional career, she has achieved peak performance sales results and awards year after year. She captures the vision of the company and drives it forward with enthusiasm and expertise. Her commitment to providing an exceptional customer experience has been the key to her success.

Richard Matthews, Interim Financial Controller
Richard Matthews joined the InsuraGuest team in March 2019 as the interim financial controller. Leading the Finance and Audit team, Matthews is responsible for the delivery of financial services such as accounting, treasury, reporting, budgeting and insurance management, in accordance with legislative requirements and organizational policies and strategies. He has over 30 years of experience in providing professional services across a broad range of finance areas including compliance, business process, audit, and financial reporting. He holds a degree in accounting from the University of Utah and is a licensed CPA in the state of Utah.

Roger Bloss, Corporate Consultant & Board Advisor
Roger Bloss joined InsuraGuest in August of 2019 to advise the company and its board on hotel transactions, contributing his knowledge from more than 40 years in the hospitality industry. Bloss previously served in executive positions with several major hotel franchise companies and in 1996 founded Vantage Hospitality Group hotel brands. Under his leadership, Vantage became a Top 10 global hotel company and made the Inc. 500/5000 list of Americas’ fastest-growing private companies for eight straight years. Bloss was named Lodging Magazine’s “Innovator of the Year” in 2006 and 2010, and in 2009 earned a spot on HSMAI’s “Top 25 Extraordinary Minds in Sales and Marketing.” Bloss joined Red Lion Hotels Corporation (RLHC) in September 2016 in conjunction with the acquisition of Vantage.

Jim Kilduff, Board Advisor
James “Jim” C. Kilduff has nearly 40 years of experience in the insurance and risk management sectors. He is a dynamic and energetic team leader and builder with extensive experience in the changes affecting the insurance business through Gas, alternative distribution, insurtechs and program business. His skillset includes experience as chief insurance officer with Outdoorsy Insurance Group, CEO with Harbor Hill Solutions Inc., and senior vice president and chief marketing officer with State National Insurance Companies. His career has spanned MGA creation and management, insurance company management, business development and underwriting, primary insurance and reinsurance.

Don Archibald, Board Advisor
Don Archibald brings to InsuraGuest’s advisory board 54 years of experience as an insurance agent. Archibald is the founder and former owner of Archibald Clarke and Defieux (ACD Insurance), as well as the co-founder and former equity partner of Sussex Insurance, and an agent with Sussex since 2014.

InsuraGuest Technologies, Inc. (ISGIF), closed Tuesday's trading session at $0.2475, up 15.0628%, on 27,855 volume. The stock's 52-week low/high is $0.000000999/$0.000199999.

Recent News

• InvestorNewsBreaks - InsuraGuest Technologies Inc. (TSXV: ISGI) (OTCQB: ISGIF) Announces OTCQB Listing, DTC Eligibility
• InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTCQB: ISGIF) Expands Reach with New Global Partnership
• InvestorNewsBreaks - InsuraGuest Technologies Inc. (TSX.V: ISGI) (OTCQB: ISGIF) Announces Insurance Coverage Expansion to Cover Entire Hotel Premises

Cybin Inc. (NEO: CYBN) (OTC: CLXPF)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (OTC: CLXPF).

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) was featured today in a publication from PsychedelicNewsWire, examining how, in the last few years, various scientific studies have shown how different psychedelic substances such as LSD, MDMA and magic mushrooms may help treat mental health conditions. This credible and extensive research has only propelled these drugs further into the mainstream.

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (OTC: CLXPF), closed Tuesday's trading session at $1.68, up 4.3478%, on 1,352,149 volume. The average volume for the last 3 months is 373,735 and the stock's 52-week low/high is $0.003299999/$0.067100003.

Recent News

• Former Vancouver Firefighter Declares Psychedelic Drug Saved His Life
• You Don't Have to Take Psychedelics to Benefit from Them - Here's How
• PsychedelicNewsBreaks - Cybin Inc. (NEO: CYBN) Poised to Provide Breakthrough Therapy for MDD

CannAssist International Corp. (OTCQB: CNSC)

The QualityStocks Daily Newsletter would like to spotlight CannAssist International Corp. (OTCQB: CNSC).

CannAssist International (OTCQB: CNSC) is a biotechnological pharmaceutical and wellness company marketing its exclusive Xceptol consumer brand. The company is the owner of Xceptor Labs, which uses proprietary technology to create Xceptol CBD products. The company complex has better absorption than currently marketed oil-based products — a key advantage when assessing products' effectiveness. Also today, the company was featured in the 420 with CNW by CannabisNewsWire.

CannAssist International Corp. (OTCQB: CNSC), owner of Xceptor Labs, is a biotechnological pharmaceutical and wellness company marketing the Xceptol consumer brand.

CannAssist, a Delaware corporation, was established in May 2017 and is headquartered in San Diego County, California.

2018 Farm Bill and CBD Market Size

Signed into law in December 2018, the Agriculture Improvement Act of 2018 (2018 Farm Bill) removed hemp from its classification as a Schedule I drug under the Controlled Substances Act of 1970.

There are over 100 known cannabinoids within the hemp plant. The two most commonly utilized cannabinoids are THC (tetrahydrocannabinol) and CBD (cannabidiol). Cannabinoids have been shown to affect the endocannabinoid system within the human body, which is why CBD has demonstrated effectiveness as a therapeutic option when delivered through the right absorption avenues.

The 2018 Farm Bill is expected to have a sustained impact on the growth of the cannabidiol market and related sectors. In 2018, the global cannabidiol market was valued at $4.6 billion, and it’s expected to increase almost sixfold by 2025, reaching $23.6 billion (https://ibn.fm/PL6PO).

This growth is expected to provide multiple opportunities to CannAssist and its high-quality, high-performance brands, including products currently under development. Based on current revenue from licensing agreements, retail sales and the Xceptol brand’s international distribution, the company expects to reach first-year sales of $5 million. With additional products in the pipeline and an unwavering commitment to quality and effectiveness, the company expects to see steady sales growth in the years ahead.

Xceptor Labs

Xceptor Labs is an R&D and raw material manufacturing company that partners with TakaUSA, in Coppell, Texas, for contract manufacturing and production services.

CiBiDinol Technology

Xceptor Labs’ technology, CiBiDinol, is formulated using a proprietary process developed by CannAssist Founder Mark Palumbo. It is specifically designed to address many critical issues with oil-soluble CBD molecules, including delivery, bioavailability and short shelf-life. This technology provides the basis for Xceptor Labs and Xceptol consumer products.

CiBiDinol is believed to provide CBD in a format that is more in line with the body’s natural bioactivity. The company’s proprietary processes are used to combine CBD molecules with penetration enhancing cyclodextrin, effectively modifying the CBD molecule’s surface and rendering it water dispersible. This technology enhances absorption through the skin and gut.

The company believes that CBD products created using its CiBiDinol technology offer more predictable potency and enable reduced dosage requirements. This technology clears the way for a wide variety of products, including many oil-soluble active ingredients and highly effective consumer product applications.

Independent Testing

Third-party testing has confirmed that products made with CiBiDinol demonstrate a 400 percent increase in skin penetration as compared to regular CBD in oil carriers alone, as well as a 300 percent higher absorption rate in the gut. The company believes that the results indicate that the amount of CBD needed to achieve targeted endpoints can be significantly lower, resulting in lower costs for manufacturers and consumers with little to no side effects.

“Oversight of manufacturing and third-party testing of this ingredient produced consumer products designed to provide clinicians and consumers safe, effective, and affordable treatment options to address their health and wellness concerns,” Palumbo said in a news release.

CiBiDinol is currently being evaluated for safety by the National Science Foundation for Global Recognition and has been submitted to the FDA’s bulk drug substance program. The company is developing a commerce pathway in each state’s pharmaceutical distribution network through the National Board of Pharmacies. The company aims to capture increasing market share through product extensions and advancements by seeking critical third-party analysis and physician feedback regarding its proprietary technology’s attributes. Xceptor Labs intends to offer licensing arrangements for brand-consumer companies.

Xceptol Products

CiBiDinol technology is the foundation for Xceptor Labs and the Xceptol line of products, including topical creams, capsules, tinctures and pet drops. The Xceptol line began launching its products in September 2020, and it currently has five National Drug Code topical pain creams utilizing ingredients registered with the FDA.

Xceptol products will be sold online, through Range Me, as well as through national and international retail and pharmaceutical distributors. Marketing for Xceptol products is planned through multiple social media campaigns including using celebrities and former athletes associated with Freedman Sports Promotional Relations.

Xceptol is establishing sales channels in North America, Central America, South America, South Africa, the EU, the UK and the Philippines.

Management Team

Mark Palumbo, CEO and Founder, is an entrepreneur, scientist and executive with over 30 years in the health care, laboratory and manufacturing industries. His entrepreneurial endeavors include a successful personal care industry distribution company, a currently owned and operated tissue culture laboratory and Xceptor Labs, now part of CannAssist International.

Marla Palumbo, President, is a health care professional and registered nurse with over 30 years of experience in the industry. She handles sales, patient advocacy, patient care and general management. Marla Palumbo has effectively developed and grown a personal care distribution company with significant year over year increases in sales. Her management and organization skills were instrumental in the early development of Xceptor Labs, leading to its CannAssist International public company status.

Dr. Rahul Dixit, MD, Medical Director, is a doctor of gastroenterology at Providence St. John’s Medical Center in Santa Monica, California. He was part of a double fellowship with the University of Miami in Gastroenterology and Hepatology/Liver Transplant at Johns Hopkins Hospital. He has over 20 years of experience with cannabis and hemp-related products.

Takako McGowan, Managing Director, Founding Member and Owner of TakaUSA, brings 40 years of experience in manufacturing and consumer product research & development to the CannAssist team.

Camron Elizabeth, Managing Director-Sales and Marketing, is an entrepreneur and leader who has brought immense success to the companies with whom she has worked. As Founder and CEO of Platinum Pack, Elizabeth was responsible for all aspects of its success in bringing products from concept to completion and successful sell-through on the retailer’s shelf. She has been in the beauty industry for over 40 years.

Benjamin Perlstein, VP of Operations, has been a part of the health care and business development field for over 25 years. As a surgical technologist, he has experience as a clinical application specialist and materials manager.

Braden Traub, Director of Marketing and Customer Development, is an entrepreneur and business owner with 10 years of experience in the health and fitness industries. Traub also has skills and experience as a tax resolutionist and legal document preparer.

Safe Harbor for Forward-Looking Statements

Forward-looking statements are inherently subject to risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, the following: the timing and nature of any capital raising transactions; the Company’s ability to offer products and services for use by customers in existing and new markets; the Company’s ability to deliver in a timely fashion and to its customers’ satisfaction the products purchased; the risk of competition; its ability to find, recruit and retain personnel with knowledge and experience in selling products and services in existing and new markets; its ability to manage growth; and general market, economic and business conditions. Additional factors that could cause actual results to differ materially from those anticipated by the Company’s forward-looking statements are under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in its Annual Report on Form 10-K for the fiscal year 2019 and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, all filed with the Securities and Exchange Commission. Forward-looking statements are made as of the date hereof, and the Company expressly disclaim any obligation or undertaking to update forward-looking statements.

CannAssist International Corp. (OTCQB: CNSC), closed Tuesday's trading session at $0.121, even for the day, on 1 volume. The average volume for the last 3 months is 300 and the stock's 52-week low/high is $0.000099999/$0.100000001.

Recent News

• CannAssist International Corp. (CNSC) Proprietary Tech Is Core of CBD Products with Better Absorption
• 420 with CNW - Could Canna-Tourism Trigger Economic Recovery?
• CBDNewsBreaks - CannAssist International Corporation (CNSC) Leverages Proprietary Technology to Stand Distinct in Surging Market

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) was featured today in a publication from MiningNewsWire, examining how similar to other industries, mining is an energy-intensive industry. The only difference is that the processes involve a lot of crushing, digging and processing of minerals, which consumes a lot of power. Mines also operate 24 hours a day on every day of the week. Now that climate action is a priority under the Sustainable Development Goals (“SDGs”), many industries, including mining, are looking for solutions to decrease their emissions in a bid to incorporate more environmentally friendly approaches to mining, which will in turn help the planet.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

• White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
• Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
• Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

• Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
• Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
• Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

• La Sal Complex (Utah)
• Whirlwind Mine (Colorado/Utah)
• Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Tuesday's trading session at $4.14, off by 3.0445%, on 3,707,324 volume. The average volume for the last 3 months is 3,953,280 and the stock's 52-week low/high is $0.349999994/$4.48999977.

Recent News

• Solar Microgrids Could Help Decarbonize Mining Operations
• Best Penny Stocks To Buy For February 2021? 4 Energy Stocks To Watch
• MiningNewsBreaks - Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Enters Strategic Partnership to Reestablish US REE Production

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF)

The QualityStocks Daily Newsletter would like to spotlight Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF).

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6A) (OTC: MOTNF) was highlighted today in a publication from Green Car Stocks, examining how StoreDot, an Israeli lithium-ion battery company has developed lithium-ion (li-ion) batteries that can be fully charged in as few as five minutes. Manufactured on standard production lines by Eve Energy in China, these fast-charge batteries are a big step towards building EVs that can charge as fast as a conventional petrol or diesel car can refuel. Although authorities have gone to great lengths to make EVs more affordable and to increase the number of public charging stations, range anxiety remains a primary concern among most drivers, says StoreDot CEO Doron Myersdorf. Also today, the company was featured in a GreenCarNewsBreaks from Green Car Stocks, examining how MOTNF announced that Michael Andretti, chairman and CEO of Andretti Autosport and founding partner of The Andretti Group, has been appointed to the advisory board of PowerTap Hydrogen Fueling Corp. (“PowerTap”). Clean Power invested in PowerTap las year as part of its hydrogen sector investment strategy. Andretti, a well-known second-generation auto racing driver, retired from driving in 2003 and, since then, has focused on building the Andretti Autosport brand. To view the full press release, visit http://ibn.fm/MOO1j

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) is an investment holding company that focuses on investing in and providing early-stage financing to both public and private businesses. Since its original listing with the Canadian Stock Exchange (“CSE”) on January 23, 2019, the company has made investments in a number of different businesses in a variety of industries, including the energy and cannabis sectors. As per the company’s investment policy, its primary goal is to identify and capitalize on high-return investment opportunities presenting the ability to achieve capital appreciation and liquidity.

Clean Power Capital continues to be opportunistic in evaluating prospects across the renewable energy, bio-medical, pharmaceutical and naturopathic sectors, both as an investor and as an operator. The company’s main focus at the moment is to identify such opportunities in the renewable energy industry, including wind, solar and geothermal power and hydrogen and fuel cell technologies, as well as in the biomedical, pharmaceutical and naturopathic sectors, which may include medical or recreational cannabis.

Clean Power Capital currently has 10 investments in a variety of sectors and successfully held nearly C$120 million in investments during the past fiscal year (https://ibn.fm/8oktZ). It returned capital to its shareholders through the distribution of its interest in AgraFlora Organics International Inc. in May 2020 (https://ibn.fm/FRAvq).

Headquartered in Vancouver, British Columbia, Clean Power Capital was formerly named Organic Flower Investments Group Inc. As of November 10, 2020, the company officially changed its name to Clean Power Capital and started trading on the CSE under new ticker symbol ‘MOVE’.

PowerTap Acquisition, Hydrogen Fueling Infrastructure Collaboration

In alignment with its updated investment policy, a reconstituted investment committee and a revised strategy to reflect its focus on the renewable energy market, Clean Power Capital recently completed the acquisition of a 90 percent equity interest in California-based PowerTap Hydrogen Fueling Corp.

Leveraging an impressive portfolio of IP and advanced deployed technologies developed over two decades via substantial investments and partnerships, PowerTap is working on building and expanding a hydrogen filling station network, initially across North America. The company believes that its platform has a significant advantage over other hydrogen fueling stations, because it has a smaller physical footprint and further has the capacity to produce hydrogen fuel on site. As most other hydrogen fueling stations buy hydrogen for storage at higher costs, PowerTap’s model is believed to be exponentially more cost-effective and expandable.

Clean Power Capital’s investment and acquisition will allow PowerTap to step up its efforts and begin work on the hydrogen fueling station network in stages, starting with engineering and design, ongoing development of PowerTap’s third generation product and, finally, licensing & permitting and site preparation. Development is expected to begin in Q4 2021 with engineering and design. Overall, the initial portion of the project is expected to cost $17 million, with Clean Power Capital and PowerTap planning to secure government financing and credit, as well as equity, debt and convertible debt offerings, to fund the infrastructure’s development.

PowerTap technology is already deployed across multiple hydrogen fueling stations in public and private enterprises spanning California, Maryland, Massachusetts and Texas. The company plans to deploy its hydrogen fueling infrastructure at existing truck stops and gas stations across the country, beginning with up to 1,000 stations within the next three to five years. At the moment, there are roughly 70 active hydrogen fueling stations operational and available to consumers in the United States.

Hydrogen Industry Outlook

The project is expected to bring significant opportunities for PowerTap and Clean Power Capital on the fast-growing hydrogen market, driven by a worldwide focus on clean energies and environmentally friendly fueling solutions for the transportation industry.

Hydrogen-powered vehicles come with tremendous advantages over gas, diesel and even electric vehicles in terms of cost per mile, fueling time and driving range, as well as boasting significantly lower emissions. Well-established vehicle manufacturers such as Hyundai, Toyota, Daimler and Volvo are already including hydrogen-powered cars in their product lineups, and Nikola Motors has announced plans to manufacture hydrogen electric long-haul vehicles.

“As an experienced developer of technology in an important area that is finally having its time as a green but also economically compelling energy option, PowerTap is intent on becoming a leading part of the multi-billion dollar hydrogen fueling space,” PowerTap CEO Raghu Kilambi explained in a news release on October 28, 2020 (https://ibn.fm/oaXem).

A recent industry report developed by a coalition of major oil and gas, power, automotive, fuel cell and hydrogen companies indicates that the sector is expected to grow to $140 billion a year in revenue by 2030, creating 700,000 jobs in the U.S. alone (https://ibn.fm/UMI5q). According to Fuel Cell and Hydrogen Energy Association President Morry Markowitz, the sector could expand to $750 billion a year in revenue and 3.4 million jobs by 2050.

The U.S. is already engaged in the hydrogen economy, having more than half of the global number of fuel cell vehicles and investing hundreds of millions of dollars a year, but the country can greatly expand its global energy leadership by scaling up operations in the hydrogen economy, per the industry report.

With the upcoming change in administration in January 2021, the U.S. is expected to renew its commitment to clean energy. Moreover, the U.S. federal government is expected to invest significantly in clean energy and related infrastructure, including hydrogen, according to PowerTap.

“As the U.S. federal government has previously invested in the PowerTap technology, we are optimistic that we will have a seat at the table when USA clean energy/hydrogen infrastructure spending initiatives are designed,” Kilambi added.

Management Team

Joel Dumaresq is the CEO and interim CFO of Clean Power Capital. He is a proven executive with extensive operational and senior management experience in mining, energy and alternative energy, as well as the cannabis and hemp space. Dumaresq began his career in the corporate finance space, having spent 12 years with RBC Dominion Securities. He brings 30 years of experience in the financial sector to the company, has been instrumental in raising over $250 million in venture capital finance, and he has personally managed a number of successful public listings.

Brendan Purdy serves as a director of Clean Power Capital. An experienced businessperson who has led five different companies, Purdy brings years of experience in different industries, including cannabis, blockchain and data security, gaming, mining and energy, and finance and law. He received a graduate degree from the University of Ottawa and an undergraduate degree from the University of Western Ontario.

Theo van der Linde serves as a director of Clean Power Capital. He is a Chartered Accountant with over 20 years extensive experience in finance, reporting, regulatory requirements, public company administration, equity markets and financing of publicly traded companies. He has served as a CFO & Director for a number of TSX Venture Exchange- and Canadian Securities Exchange-listed companies over the past several years. His industry experience spans the financial services, manufacturing, oil & gas, mining and retail industries. More recently, van der Linde has been involved with future use trends of natural resources, as well as other disruptive technologies.

Raghu Kilambi is the CEO and CFO of PowerTap Hydrogen. He is a seasoned investor and entrepreneur with over 25 years of global business experience in public and private investments, building businesses and creating shareholder value. He has raised over $1 billion of equity and debt capital for private and public companies and been involved in many M&A acquisitions and exits.

Clean Power Capital Corp. (OTC: MOTNF), closed Tuesday's trading session at $2.19, off by 2.6667%, on 165,825 volume. The average volume for the last 3 months is 232,515 and the stock's 52-week low/high is $1.41999995/$28.75.

Recent News

• Factory Produces EV Batteries That Can Be Fully Charged in Five Minutes
• GreenCarNewsBreaks - Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) Appoints Michael Andretti to PowerTap Advisory Board
• GreenCarNewsBreaks - Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6A) (OTC: MOTNF) Among Leading Life Science Firms Comprising CSE Composite Index

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF)

The QualityStocks Daily Newsletter would like to spotlight PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF).

PlantX Life Inc. (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF), a multifaceted marketplace providing consumers all things plant based, has entered into a charitable partnership with After-School All-Stars. As part of the partnership, PlantX will facilitate donations to the nonprofit organization designed to support students and their families; PlantX customers can be involved in the philanthropic endeavor by donating on PlantX websites. To view the full press release, visit https://ibn.fm/Sj9a8

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) aims to redefine the plant-based community through e-commerce, with a core objective of becoming the most trusted and convenient destination for people living plant-based lives. PlantX is a multifaceted marketplace providing consumers all things plant-based ranging from an efficient e-commerce experience, connecting consumers with interactive PlantX brick-and-mortar stores, and a PlantX home delivery system for products, meals, recipes and more.

PlantX is a high-growth technology company focusing on consumer-packaged goods (“CPG”) for the plant-based opportunity. The PlantX platform aims to serve as the digital face of this community with its one-stop-shop for everything plant-based, including:

• An easy-to-use e-commerce shopping experience featuring the following:
• Plant-based grocery items (from all your pantry needs to vitamins, cosmetics and even pet food)
• Meal delivery with recipes created by well-known plant-based chefs throughout the world
• Plant shop – delivering a wide variety of affordable indoor houseplants to homes across Canada and the U.S.
• Easy to follow plant-based recipes every week
• Partnerships with restaurants, nutritionists, chefs and brands
• A community of like-minded individuals
• State-of-the-art flagship PlantX locations

Since first launching in February 2020, PlantX Life has offered various services available through its comprehensive platform. This online marketplace features over 10,000 items across diverse product categories such as pantry items, beverages, personal care, pet food and indoor plants. In addition, PlantX has collaborated with renowned chefs and nutritionists to create 20 unique and pre-made meals delivered to the comfort of your own home.

Headquartered in Vancouver, Canada, PlantX’s mission is to spearhead the plant-based movement, celebrate and promote health and wellbeing, raise plant-based awareness in a hyper-palatable world, connect with global consumers and forge a welcoming plant-based community.

The company currently reports 4 million stock options and 24 million warrants outstanding, with a total of 88,832,159 shares issued and outstanding and a total market cap of $89.9 million on January 18, 2021. PlantX has continued to catalyze its capital markets dynamics by applying to list its common shares on the Nasdaq Capital Market (“NASDAQ”). The company’s common shares are eligible for electronic clearing and settlement through The Depository Trust Company (“DTC”) in the United States.

Market Outlook

With its comprehensive e-commerce platform, PlantX is strongly positioned for a prominent role in the fast-growing plant-based food market, e-commerce and the online food delivery sectors. The global plant-based food market is expected to reach $74.2 billion by 2027, expanding at a CAGR of 11.9%. Similarly, the online food delivery market has steadily grown, especially during the current pandemic. This trend seems here to stay. In the United States alone, the sector is expected to report $28.5 billion by 2024, with companies such as UberEats experiencing 152% increases in food deliveries in the summer of 2020.

Complementary to these trends, and as a result of the COVID-19 pandemic, online sales and digitization have also both grown exponentially in 2020. Grocery shopping has seen a remarkable transition to e-commerce, with online grocery sales growing by 53% in 2020. Amid the pandemic-imposed physical interactions and related consumer behavior change, large retailers have been compelled to meet this surge in e-commerce demand. For example, Whole Foods Markets has increased its online sales capacity by over 60% in 2020. The global meal kit delivery system is also becoming increasingly popular and is expected to achieve a market value of $19.92 billion by 2027, expanding at a CAGR of 12.8%.

PlantX aims to capitalize on this anticipated exponential market growth of the plant-based, e-commerce and home-delivery industries.

Digital Platform for the Plant-Based Community

The digital interface provided by PlantX spans a health and wellness initiative that offers thousands of plant-based products, meal delivery, indoor plants, recipes and a community space for those who are like-minded about plant-based products and healthy lifestyles. PlantX has been compared to Amazon, except with a focused tailored selection of plant-based offerings.

PlantX provides everything a consumer needs for plant-based living at the click of a button. With PlantX, customers can:

• Shop
• Find recipes
• Read blogs
• Join a community forum
• Listen to podcasts
• View cosmetics
• Research vitamins
• Purchase plant-based pet foods
• Read corporate updates
• Subscribe to an insightful newsletter

The company’s website was designed with a user-friendly interface that allows customers to visit the site and easily find what they need. Forums for communicating with a plant-based community make it easier to swap recipes or locate the best restaurants serving vegan and vegetarian-friendly cuisine.

PlantX Flagship Locations – British Columbia (Canada), San Diego (California), & the State of Israel

PlantX will link the e-commerce platform to flagship brick-and-mortar stores for a highly sensory customer experience. This is anticipated to drive corporate growth and global brand recognition.

These PlantX branded flagship locations will first launch in:

• Squamish, British Columbia, Canada
• San Diego, California, United States
• Tel Aviv, State of Israel

Customer engagement, education and creating a global plant-based community will be furthered through this initiative.

PlantX Restaurant Partnerships

With consumers becoming better informed and more health and environmentally conscious, a growing number of restaurants will start catering to the needs of customers who are vegan, vegetarian, have food-allergies (or specialized diets), or simply want to eat healthier.

PlantX proactively aims to support this change and help restaurants meet the needs of the plant-based community. Restaurants that want to increase revenue, drive traffic and make an impact can therefore partner with PlantX to better serve their customers by expanding and refining their menus.

Future Goals for PlantX Life

Having successfully completed all of the milestones that PlantX had set-out to achieve in the second half of 2020, PlantX strives to continue scaling through organic growth, strategic partnerships and accretive M&A opportunities. The upcoming plans from PlantX includes a global expansion strategy for distribution in North America, Europe and Israel.

Verticals launched in 2020 include:

• New meals and programs by renowned chefs
• Flagship PlantX locations
• PlantX branded goods
• United States meal delivery and LIV
• Online peer-to-peer fitness

Management Team

Sean Dollinger, the Founder of PlantX Life Inc., has had a very active professional career that started when he was only 17. While still in college, he started a delivery service that soon became one of Canada’s largest delivery firms (before companies like Postmates and Uber Eats ever existed). In 2014, Mr. Dollinger founded Namaste Technologies, the largest international e-commerce distributor of vaporizers and accessories. He brought Namaste public and turned it into a $1.2 billion business in two years. After finding a plant-based diet himself, and seeing the massive benefits that it provided for him, he decided he wanted to find a way to give back to the community and focus on something he loves. PlantX Life was born from this desire and became his passion project. He truly walks the talk.

Julia Frank is the CEO of PlantX Life. She has an MBA in digital entrepreneurship, and, in her past roles, she set up renowned strategies for large corporations like BMW and Daimler in Germany. Beyond her professional business prowess, Ms. Frank finds tremendous joy in preparing delicious and nutritious plant-based meals and is the face of the company. She practices a healthy and active lifestyle that includes experiencing as many cultures as possible to add more knowledge of the industry at large. This globally inclusive perspective gives her the unique advantage of being able to see plant-based living from all angles.

Lorne Rapkin, CPA, CA, LPA, is the President and CFO of PlantX Life and is also a partner at Rapkin Wein LLP. He has experience with clients in almost every industry, including finance, professional services, real estate, automotive, media and manufacturing. Mr. Rapkin works very closely with investment and public firms, seeking to comply with IFRS accounting standards. His roles often require him to work with management on go-public transactions, acquisitions and mergers. His keen attention to detail is an asset to any client he works with, and PlantX is no exception.

Alex Hoffman is the company’s CMO and has spent the last 10 years in the creative field cultivating her passion for design and appreciation for beauty. This is apparent in all of the creative decisions and outcomes seen at PlantX. Her role within the company is to oversee all of the brand marketing activities, establish and execute key processes for rapid growth, and work closely with management to refine the brand’s message for key segments and emerging opportunities. She has a sharp vision for exactly what’s needed to convey the company’s core messages and principles to both the public and investors, and she is a visionary with respect to creative marketing ideas and concepts.

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), closed Tuesday's trading session at $1.15, off by 2.5424%, on 303,531 volume. The average volume for the last 3 months is 183,253 and the stock's 52-week low/high is $0.05/$17.9899997.

Recent News

• InvestorNewsBreaks - PlantX Life Inc. (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF) Partners with After-School All-Stars NonProfit to Support Students, Families
• InvestorNewsBreaks - PlantX Life Inc. (CSE: VEGA) (FRA: WNT1) (OTCQB: PLTXF) Achieves DTC Eligibility
• PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Is 'One to Watch'

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

Friendable (OTC: FDBL), a mobile technology and marketing company, today announced the latest results, activity and growth data related to artist sign-ups and registrations on its Fan Pass live streaming artist platform. According to the update, Fan Pass recorded its largest number of inquiries and overall artist sign-ups on the platform, totaling 318 for January 2021. This represents 248 new sign-ups (up from 70 in December 2020), representing 354% growth in a one-month or 30-day period. To view the full press release, visit https://ibn.fm/IYQiY

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

• Live performances or online concerts
• Backstage meetups before, during or after events
• Livestreams of studio sessions
• Behind-the-scenes footage of music video and photo shoots
• Special interviews and one-on-one videos
• Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Tuesday's trading session at $0.016, off by 1.8405%, on 3,944,170 volume. The average volume for the last 3 months is 3,038,819 and the stock's 52-week low/high is $2.06999993/$15.0500001.

Recent News

• InvestorNewsBreaks - Friendable Inc. (FDBL) Announces New Record Metrics for Fan Pass Live Streaming Platform
• Friendable (FDBL) Builds On Music Fans Engagement Success with Growing Services for Performers
• InvestorNewsBreaks - Friendable Inc. (FDBL) Launches Pro Services Offering Designed to Provide Additional Artist Support

Kaival Brands Innovations Group Inc. (KAVL)

The QualityStocks Daily Newsletter would like to spotlight Kaival Brands Innovations Group Inc. (KAVL).

Friendable (OTC: FDBL), a mobile technology and marketing company, today announced the latest results, activity and growth data related to artist sign-ups and registrations on its Fan Pass live streaming artist platform. According to the update, Fan Pass recorded its largest number of inquiries and overall artist sign-ups on the platform, totaling 318 for January 2021. This represents 248 new sign-ups (up from 70 in December 2020), representing 354% growth in a one-month or 30-day period. To view the full press release, visit https://ibn.fm/IYQiY

Kaival Brands Innovations Group Inc. (KAVL) is focused on growing and incubating innovative and profitable products into mature, dominant brands. It aims to develop internally, acquire or exclusively distribute these products, helping them grow into market-share leaders by providing superior quality that is recognizable in their individual industries.

Formerly known as Quick Start Holdings Inc., the company changed its name to Kaival Brands Innovations Group Inc. (also known as Kaival Brands) in July 2019. Headquartered in Grant, Florida, the company commenced business operations on March 9, 2020.

Bidi™ Stick – Revolutionizing the Vaping Experience

On March 9, 2020, Kaival Brands entered into a partnership with Bidi Vapor LLC. The latter granted Kaival Brands exclusive global distribution rights for the innovative Bidi™ Stick.

Bidi™ Stick is a completely self-contained disposable product that is tamper-proof and recyclable. The innovative product is made from high-quality components and equipped with a long-lasting battery and class A nicotine. Its product engineering also includes a sensitivity control system, along with a proven mechanism designed to help identify and eliminate counterfeit products.

Available in 11 flavors, the Bidi™ Stick offers a premium vaping experience for adult consumers only. From its packaging design to its marketing strategies, Bidi Vapor makes sure that everything is compliant with government regulations.

On March 31, 2020, Kaival Brands partnered with QuikfillRx Digital as a digital service provider to help promote and commercialize the Bidi™ Stick. As a direct result of the partnership, Kaival Brands received back-to-back orders for the vaping device, totaling approximately $135,000, from sizable national convenience chains.

On September 8, 2020, the company announced that Bidi Vapor had submitted its Premarket Tobacco Product application (PMTA) to the U.S. Food and Drug Administration (FDA) for review. In total, over 285,000 pages of research, studies and surveys were submitted to support the application of Bidi™ Stick’s 11 variants.

“We are confident that, upon review, the FDA will authorize Bidi Vapor’s Bidi™ Stick for continued marketing in the United States,” Niraj Patel, President and CEO of Kaival Brands, stated in a news release (http://nnw.fm/unAyG).

Bidi Vapor is an industry leader in recycling – a position that was furthered through the creation of the Bidi Cares Initiative. The program encourages users to recycle their used Bidi™ Sticks instead of trashing them. As motivation, Bidi Vapor offers a free Bidi™ Stick for every 10 used devices recycled by a consumer. Kaival Brands is the exclusive recycling provider for the initiative.

Partnership Impact and Market Outlook

Bidi Vapor is a related party to Kaival Brands, as it is owned by Kaival Brands CEO Nirajkumar Patel. Patel is also the majority stockholder of Kaival Brands, placing both entities under common control.

The partnership has already had a positive impact on Kaival Brands, helping the company expedite growth, as evidenced by its Q2 financial results. According to Kaival Brands’ consolidated fiscal results for the quarter that ended on April 30, 2020, its revenues grew to approximately $22.5 million from no revenue in the same quarter of 2019. The company also scored a gross profit of $4.2 million for the three-month period. Net income was reported at $2.8 million for the quarter, compared to a net loss of about $4,000 in the second quarter of 2019. The company ended the second quarter of 2020 with a cash balance of $2 million (http://nnw.fm/44sq4).

The positive results are primarily an effect of Bidi™ Stick distribution amid the growing worldwide demand for high-quality vape products, as Patel explained in a news release. “Our focus now is to continue to increase revenues by increasing Bidi Vapor’s market share in the vaping industry,” he added.

Internationally, Kaival Brands has already taken steps to expand distribution of the Bidi™ Stick into Guam, Canada, the European Union, the United Kingdom, Australia and New Zealand.

To this end, the company has set up a market engagement and sales force to reach a higher volume of retail and wholesale customers. It also created a dedicated customer support team to provide high-quality service and an enhanced customer experience.

Kaival Brands is dedicated to developing innovative and viable options for adults who use tobacco and vape products and want a premium experience. The company wants to set higher standards to transform perceptions and elevate consumer experience in the vape and CBD industries, with a goal of increasing market share in the ever-growing vaping industry. In 2019, the reported global market for the vaping industry alone was $12.4 billion. These forecasts indicate a potential CAGR of 23.8% through 2027.

Cancellation of 300 Million Shares of Common Stock

In August 2020, the company canceled 300 million shares of common stock, marking a 52.1 percent reduction in its issued and outstanding shares of common stock (http://nnw.fm/W7s9T). Currently, the company’s outstanding common shares total 277,282,630. The cancelation was done in exchange for three million shares of Series A Preferred Stock. The Series A Preferred Stock cannot be converted before November 2023, barring any event that may trigger early conversion.

According to Patel, this move will benefit all shareholders and help maintain stability of the market pricing of remaining common stock. The overall goal is to increase value for long-term investors.

Management Team

Nirajkumar Patel is the CEO, CFO, President, Treasurer and Director of Kaival Brands and owner of Bidi Vapor LLC. In 2004, Patel received a Bachelor of Science in pharmaceutical sciences from AISSMS College of Pharmacy in Prune, India. He moved to the United States in 2005, and he continued his education at the Florida Institute of Technology, where he graduated in 2009 with a master’s degree in medicinal and pharmaceutical chemistry. He currently holds a Six Sigma Black Belt Certification.

Eric Mosser is the COO, Secretary and Director of Kaival Brands. Mosser attended Arizona State University, where he studied business management. In 2004, he graduated from Rio Salado College with an associate degree in applied science in computer technology.

Kaival Brands Innovations Group Inc. (KAVL), closed Tuesday's trading session at $1.23, up 2.50%, on 260,147 volume. The average volume for the last 3 months is 631,817 and the stock's 52-week low/high is $2.07999992/$9.5998001.

Recent News

• InvestorNewsBreaks - Kaival Brands Innovations Group Inc. (KAVL) Announces New Bidi Pouch Product
• InvestorNewsBreaks - Kaival Brands Innovations Group Inc. (KAVL) Announces It Has Begun Process for NASDAQ Uplisting
• InvestorNewsBreaks - Kaival Brands Innovations Group Inc.'s (KAVL) Bidi Stick No. 1 Electronic Nicotine Delivery System Offering, Sees Market Growth of Over 900%